7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial.
Saved in:
| Title: | 7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial. |
|---|---|
| Authors: | Zhou, C.1 (AUTHOR), Xiong, A.1 (AUTHOR), Zhao, J.2 (AUTHOR), Li, W.3 (AUTHOR), Bi, M.3 (AUTHOR), Chen, J.4 (AUTHOR), Li, K.4 (AUTHOR), Miao, L.5 (AUTHOR), Mao, Y.6 (AUTHOR), Wang, D.7 (AUTHOR), Liu, C.8 (AUTHOR), Zeng, A.9 (AUTHOR), Li, R.10 (AUTHOR), Pan, Y.11 (AUTHOR), Hu, Y.12 (AUTHOR), Zhang, X.13 (AUTHOR), Niu, H.14 (AUTHOR), Du, Y.15 (AUTHOR), Sun, Y.16 (AUTHOR), Liu, Z.17 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 2, Vol. 33, pS31-S31. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.02.016 |
